Heron Therapeutics (HRTX) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Heron Therapeutics (HRTX) Misses Q1 EPS by 2c

Heron Therapeutics Announces First Quarter 2015 Financial Results and Corporate Progress

May 8, 2015 8:00 AM EDT

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Heron Therapeutics, Inc. (NASDAQ: HRTX), today reported first quarter 2015 financial results and highlighted recent corporate progress.

First Quarter and Recent Corporate Progress:

In April 2015, the Company completed enrollment in MAGIC, its Phase 3 study evaluating the efficacy of SUSTOL® (granisetron injection, extended release) for the prevention of delayed-onset chemotherapy induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents. The study enrolled over 900 patients undergoing treatment for various tumor types at approximately 200 U.S. sites.

In March 2015, the Company disclosed positive... More